



- (51) **International Patent Classification:**
G16H 50/20 (2018.01) *G16B 20/00* (2019.01)
- (21) **International Application Number:**
PCT/US2022/034368
- (22) **International Filing Date:**
21 June 2022 (21.06.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/213,428 22 June 2021 (22.06.2021) US
63/329,008 08 April 2022 (08.04.2022) US
- (71) **Applicant: SCIPHER MEDICINE CORPORATION**
[US/US]; 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US).
- (72) **Inventors: GHIASSIAN, Susan;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US). **AK-MAEV, Viatcheslav R.;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US). **VOITALOV, Ivan;** 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453 (US).
- (74) **Agent: CRIPPEN, Shane M.;** Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) **Title:** METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES

FIG. 1

(57) **Abstract:** Described are methods and systems for identifying a target for therapy and treating a subject that exhibits a disease gene expression signature, comprising identifying and administering a therapy determined to revert a disease gene expression signature in a subject suffering from a disease, disorder, or condition toward a non-diseased expression signature (e.g., disease gene expression signature of a non-diseased subject).

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*